Approach to predict the contribution of cytochrome P450 enzymes to drug metabolism in the early drug-discovery stage: The effect of the expression of cytochrome b5 with recombinant P450 enzymes

Xenobiotica

Volumn 37, Issue 9, 2007, Pages 986-999

  Emoto, C ^a   Iwasaki, K ^a  

^a PFIZER INC   (United States)

Author keywords

Cytochrome b5; Cytochrome P450 (CYP); In vitro intrinsic clearance; Prediction; Relative activity factor

Indexed keywords

AMITRIPTYLINE; BUFURALOL; CYTOCHROME B5; CYTOCHROME P450; CYTOCHROME P450 1A2; CYTOCHROME P450 2C19; CYTOCHROME P450 2C9; CYTOCHROME P450 2D6; CYTOCHROME P450 3A4; DEXTROMETHORPHAN; DICLOFENAC; IBUPROFEN; IMIPRAMINE; KETAMINE; METOPROLOL; MIDAZOLAM; PROPRANOLOL; RECOMBINANT ENZYME; VERAPAMIL;

ACCURACY; ANIMAL CELL; ARTICLE; DRUG CLEARANCE; DRUG DETERMINATION; DRUG METABOLISM; ENZYME SUBSTRATE; GENETIC POLYMORPHISM; HUMAN; HUMAN CELL; LIVER MICROSOME; METABOLISM; METABOLITE; MICROSOME; NONHUMAN; PREDICTION; PROTEIN EXPRESSION;

ARYL HYDROCARBON HYDROXYLASES; BIOTRANSFORMATION; CHROMATOGRAPHY, LIQUID; CYTOCHROME P-450 CYP1A2; CYTOCHROME P-450 CYP2D6; CYTOCHROME P-450 ENZYME SYSTEM; CYTOCHROMES B5; DRUG DESIGN; HUMANS; KINETICS; MICROSOMES, LIVER; MIXED FUNCTION OXYGENASES; RECOMBINANT PROTEINS; TANDEM MASS SPECTROMETRY; XENOBIOTICS;

EID: 34748841378     PISSN: 00498254     EISSN: 13665928     Source Type: Journal    
DOI: 10.1080/00498250701620692     Document Type: Article

References (17)

1. Emoto C, Iwasaki K. 2006. Enzymatic characteristics of CYP3A5 and CYP3A4: A comparison of in vitro kinetic and drug-drug interaction patterns. Xenobiotica 36:219-233.
2. Emoto C, Murase S, Iwasaki K. 2006. Approach to the prediction of the contribution of major cytochrome P450 enzymes to drug metabolism in the early drug-discovery stage. Xenobiotica 36:671-683.
3. McGinnity DF, Parker AJ, Soars M, Riley RJ. 2000. Automated definition of the enzymology of drug oxidation by the major human drug metabolizing cytochrome P450s. Drug Metabolism and Disposition 28:1327-1334.
4. Nakajima M, Tane K, Nakamura S, Shimada N, Yamazaki H, Yokoi T. 2002. Evaluation of approach to predict the contribution of multiple cytochrome P450s in drug metabolism using relative activity factor: Effects of the differences in expression levels of NADPH-cytochrome P450 reductase and cytochrome b(5) in the expression system and the differences in the marker activities. Journal of Pharmaceutical Sciences 91:952-963.
5. Nelson DR, Koymans L, Kamataki T, Stegeman JJ, Feyereisen R, Waxman DJ, Waterman MR, Gotoh O, Coon MJ, Estabrook RW, Gunsalus IC, Nebert DW. 1996. P450 superfamily: update on new sequences, gene mapping, accession numbers and nomenclature. Pharmacogenetics 6:1-42.
6. Obach RS. 1999. Prediction of human clearance of twenty-nine drugs from hepatic microsomal intrinsic clearance data: An examination of in vitro half-life approach and nonspecific binding to microsomes. Drug Metabolism and Disposition 27:1350-1359.
7. Rodrigues AD, Rushmore TH. 2002. Cytochrome P450 pharmacogenetics in drug development: in vitro studies and clinical consequences. Current Drug Metabolism 3:289-309.
8. Soars MG, Gelboin HV, Krausz KW, Riley RJ. 2003. A comparison of relative abundance, activity factor and inhibitory monoclonal antibody approaches in the characterization of human CYP enzymology. British Journal of Clinical Pharmacology 55:175-181.
9. Spatzenegger M, Jaeger W. 1995. Clinical importance of hepatic cytochrome P450 in drug metabolism. Drug Metabolism Reviews 27:397-417.
10. Uttamsingh V, Lu C, Miwa G, Gan LS. 2005. Relative contributions of the five major human cytochromes P450, 1A2, 2C9, 2C19, 2D6, and 3A4, to the hepatic metabolism of the proteasome inhibitor bortezomib. Drug Metabolism and Disposition 33:1723-1728.
11. Venkatakrishnan K, Von Moltke LL, Greenblatt DJ. 1998. Relative quantities of catalytically active CYP 2C9 and 2C19 in human liver microsomes: Application of the relative activity factor approach. Journal of Pharmaceutical Sciences 87:845-853.
12. Walsky RL, Obach RS. 2004. Validated assays for human cytochrome P450 activities. Drug Metabolism and Disposition 32:647-660.
13. 5 on drug oxidation activities of human cytochrome P450 (CYP) 3As: Similarity of CYP3A5 with CYP3A4 but not CYP3A7. Biochemical Pharmacology 66:2333-2340.
14. Yamazaki H, Inoue K, Shaw PM, Checovich WJ, Guengerich FP, Shimada T. 1997. Different contributions of cytochrome P450 2C19 and 3A4 in the oxidation of omeprazole by human liver microsomes: Effects of contents of these two forms in individual human samples. Journal of Pharmacology and Experimental Therapeutics 283:434-442.
15. 5 in bacterial membranes. Drug Metabolism and Disposition 27:999-1004.
16. Yamazaki H, Nakamura M, Komatsu T, Ohyama K, Hatanaka N, Asahi S, Shimada N, Guengerich FP, Shimada T, Nakajima M, Yokoi T. 2002. Roles of NADPH-P450 reductase and apo- and holo-cytochrome b5 on xenobiotic oxidations catalyzed by 12 recombinant human cytochrome P450s expressed in membranes of Escherichia coli. Protein Expression and Purification 24:329-337.
17. Yamazaki H, Shibata A, Suzuki M, Nakajima M, Shimada N, Guengerich FP, Yokoi T. 1999b. Oxidation of troglitazone to a quinone-type metabolite catalyzed by cytochrome P-450 2C8 and P-450 3A4 in human liver microsomes. Drug Metabolism and Disposition 27:1260-1266.